

February 20, 2026

Betaine Powder obtained manufacturing and marketing approval in Japan as a generic prescription drug for the treatment of homocystinuria

Oji Holdings Corporation (CEO: Hiroyuki Isono, Head Office: Chuo-ku, Tokyo) hereby announces that its group company, Oji Pharma Co., Ltd. (President: Kotaro Ishikawa, Head Office: Chuo-ku, Tokyo), has obtained manufacturing and marketing approval in Japan, effective on February 16, 2026, for a generic prescription drug for the treatment of homocystinuria (generic name: betaine), marketed under the product name “Betaine Powder”.

Homocystinuria is a rare disease classified as an inborn error of amino acid metabolism. It is caused by a congenital genetic abnormality that leads to the accumulation in the body of homocysteine, a metabolite of methionine, resulting in symptoms affecting the central and peripheral nervous systems, cardiovascular system, skeletal system, eyes, and other organs.

Betaine, a therapeutic agent for homocystinuria, is a type of amino acid derived from plants and other natural sources. In light of the fact that the development of this product is rooted in the Oji Group’s philosophy of nature positive management, we have proceeded with the application for manufacturing and marketing approval.

We will market the newly approved Betain Powder in two packaging forms: plastic bottle packaging and aluminum sachet packaging.


Betaine has highly hygroscopicity; therefore, for the 180 g bottle packaging form, a plastic bottle container with a desiccant was adopted to ensure moisture protection during repeated use and storage. In addition, the newly marketed 1 g aluminum sachet packaging form is designed to ensure moisture protection while also being expected to improve portability, and to be easy to use for pediatric patients who requires smaller doses.* The launch date will be announced separately following the NHI (National Health Insurance) drug price listing.

*Based on a dosage of 50 mg/kg per administration, in the case of a pediatric patient weighing 20 kg, one 1 g aluminum sachet is assumed to be used per dose.

■ 180 g bottle packaging form 【In preparation for launch】



■ 1 g aluminum sachet packaging form 【In preparation for launch】



Oji Group will continue to contribute to society in the medical and healthcare fields, based on its nature-positive management approach.

Contact

Business Planning Department,

Oji Pharma Co., Ltd.

Phone: +81-3-3520-9888 E-mail: ojipharma-info@oji-gr.com

Public Relations and Investor Relations Department, Corporate Governance Division,

Oji Holdings Corporation <https://www.ojiholdings.co.jp/en/>

Phone: +81-3-3563-4523 E-mail: oji-holdings@oji-gr.com